溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道

Like
Comment
Favorite

溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道

智通财经03-31

【溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道】智通财经APP获悉，百健公司(BIIB.US)已同意以56亿美元收购Apellis Pharmaceuticals(APLS.US)，此举将扩大其在免疫学和罕见病领域的治疗版图，成为该公司历史上规模最大的收购交易之一。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2623584765?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-31 21:08","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2623584765","market":"us","top_or_hot":-1,"title":"溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道】</b>智通财经APP获悉，百健公司(BIIB.US)已同意以56亿美元收购Apellis \n\nPharmaceuticals(APLS.US)，此举将扩大其在免疫学和罕见病领域的治疗版图，成为该公司历史上规模最大的收购交易之一。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 21:08 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道】智通财经APP获悉，百健公司(BIIB.US)已同意以56亿美元收购Apellis \n\nPharmaceuticals(APLS.US)，此举将扩大其在免疫学和罕见病领域的治疗版图，成为该公司历史上规模最大的收购交易之一。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2623584765","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623584765","pubTimestamp":1774962488,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道】智通财经APP获悉，百健公司(BIIB.US)已同意以56亿美元收购Apellis \n\nPhar","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Doubling the Premium Acquisition of Apellis (APLS.US) Biogen (BIIB.US) Hebs on Immunology and Rare Disease Track for $5.6 Billion","themeId":"b2495f52240e7e9378faffff6c56a404","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"【溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道】智通财经APP获悉，百健公司(BIIB.US)已同意以56亿美元收购Apellis \n\nPharmaceuticals(APLS.US)，此举将扩大其在免疫学和罕见病领域的治疗版图，成为该公司历史上规模最大的收购交易之一。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}